Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models

Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models

An established pharmaceutical strategy to increase oral drug absorption of low solubility–high permeability drugs is to create nanoparticles of them. Reducing the size of the solid-state particles increases their dissolution and transport rate across the mucus barrier and the aqueous boundary layer...

Full description

Bibliographic Details
Main Authors: David Dahlgren, Erik Sjögren, Hans Lennernäs
Format: Article
Language:English
Published: International Association of Physical Chemists (IAPC) 2020-09-01
Series:ADMET and DMPK
Online Access:https://pub.iapchem.org/ojs/index.php/admet/article/view/881
id doaj-1b1f4a37cfda47a18ecb2e341b16e6a3
record_format Article
spelling doaj-1b1f4a37cfda47a18ecb2e341b16e6a32020-11-25T03:18:54ZengInternational Association of Physical Chemists (IAPC)ADMET and DMPK1848-77182020-09-018410.5599/admet.881Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion modelsDavid Dahlgren0Erik Sjögren1Hans Lennernäs2Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, SwedenDepartment of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, SwedenDepartment of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, Sweden An established pharmaceutical strategy to increase oral drug absorption of low solubility–high permeability drugs is to create nanoparticles of them. Reducing the size of the solid-state particles increases their dissolution and transport rate across the mucus barrier and the aqueous boundary layer. Suspensions of nanoparticles also sometimes behave differently than those of larger particles in the fed state. This review compares the absorption mechanisms of nano- and larger particles in the lumen at different prandial states, with an emphasis on data derived from in vivo models. Four BSC class II drugs—aprepitant, cyclosporine, danazol and fenofibrate—are discussed in detail based on information from preclinical intestinal perfusion models. https://pub.iapchem.org/ojs/index.php/admet/article/view/881
collection DOAJ
language English
format Article
sources DOAJ
author David Dahlgren
Erik Sjögren
Hans Lennernäs
spellingShingle David Dahlgren
Erik Sjögren
Hans Lennernäs
Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models
ADMET and DMPK
author_facet David Dahlgren
Erik Sjögren
Hans Lennernäs
author_sort David Dahlgren
title Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models
title_short Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models
title_full Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models
title_fullStr Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models
title_full_unstemmed Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models
title_sort intestinal absorption of bcs class ii drugs administered as nanoparticles: a review based on in vivo data from intestinal perfusion models
publisher International Association of Physical Chemists (IAPC)
series ADMET and DMPK
issn 1848-7718
publishDate 2020-09-01
description An established pharmaceutical strategy to increase oral drug absorption of low solubility–high permeability drugs is to create nanoparticles of them. Reducing the size of the solid-state particles increases their dissolution and transport rate across the mucus barrier and the aqueous boundary layer. Suspensions of nanoparticles also sometimes behave differently than those of larger particles in the fed state. This review compares the absorption mechanisms of nano- and larger particles in the lumen at different prandial states, with an emphasis on data derived from in vivo models. Four BSC class II drugs—aprepitant, cyclosporine, danazol and fenofibrate—are discussed in detail based on information from preclinical intestinal perfusion models.
url https://pub.iapchem.org/ojs/index.php/admet/article/view/881
work_keys_str_mv AT daviddahlgren intestinalabsorptionofbcsclassiidrugsadministeredasnanoparticlesareviewbasedoninvivodatafromintestinalperfusionmodels
AT eriksjogren intestinalabsorptionofbcsclassiidrugsadministeredasnanoparticlesareviewbasedoninvivodatafromintestinalperfusionmodels
AT hanslennernas intestinalabsorptionofbcsclassiidrugsadministeredasnanoparticlesareviewbasedoninvivodatafromintestinalperfusionmodels
_version_ 1724625107838566400

Similar Items